Director Michael Berman filed a Form 4 with the SEC on November 17, 2026, disclosing the purchase of 76,923 shares of InspireMD, Inc. common stock and 57,692 Series L common stock warrants on November 13, 2026, through the company's underwritten public offering.
Key Highlights
- Purchase date: November 13, 2026, through InspireMD's underwritten public offering.
- Shares acquired: 76,923 shares of common stock at a combined public offering price of $0.65 per share.
- Warrants acquired: 57,692 Series L common stock warrants, immediately exercisable at $0.65 per share, expiring November 16, 2027.
- Direct beneficial ownership following transaction: 429,509 shares of common stock held directly.
- Indirect holdings: 244,994 shares held indirectly through the Michael Berman Revocable Trust, with no transaction effected on those securities.
- Reporting person's role: Michael Berman is identified as a Director of InspireMD, Inc. (NASDAQ:NSPR).
Michael Berman's November 2026 Public Offering Participation at InspireMD
According to the filing, Michael Berman, a director of InspireMD, Inc. (NASDAQ:NSPR), acquired 76,923 shares of common stock on November 13, 2026, as part of the issuer's underwritten public offering. The filing states the combined public offering price was $0.65 per share of common stock and accompanying Series L common stock warrants. The transaction is recorded with transaction code "P," indicating a purchase in the open market or a registered offering.
In the same transaction, Berman also acquired 57,692 Series L common stock warrants, the filing disclosed. These warrants carry an exercise price of $0.65 per share, are described as "immediately exercisable," and are set to expire on November 16, 2027. The price of the derivative security is listed as $0.00, consistent with the warrants being issued as part of the combined unit price at the offering level.
Following the reported transaction, Berman directly holds 429,509 shares of InspireMD common stock, according to the filing. An additional 244,994 shares are held indirectly through the Michael Berman Revocable Trust. The filing specifies that "no transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only." The Form 4 was signed by Michael Lawless as Attorney-in-Fact for Michael Berman and filed on November 17, 2026.
What Was Disclosed
Director Michael Berman reported the purchase of 76,923 shares of InspireMD common stock and 57,692 Series L warrants at $0.65 per share through a public offering on November 13, 2026, with direct post-transaction ownership of 429,509 shares and indirect holdings of 244,994 shares via a revocable trust.





Please wait processing your request...